Vascular endothelial growth factor (VEGF) - Part 2: In endocrinology and oncology

Endokrynologia Polska

Volumn 62, Issue 5, 2011, Pages 456-464

  Kajdaniuk, Dariusz ^a   Marek, Bogdan ^a   Foltyn, Wanda ^a   Kos Kudła, Beata ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiogenesis; Cancer; CEP NET; Diabetes mellitus; Endocrine glands; Flt 1; Growth factor; Hepatocellular carcinoma; KDR; Liver; Neoplasm; Oncology; Pituitary; Thyroid; VEGF

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE B; KI 67 ANTIGEN; MESSENGER RNA; OCTREOTIDE; PROTEIN P53; RANIBIZUMAB; SOMATOMEDIN C; SOMATOSTATIN; SORAFENIB; SURAMIN; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACROMEGALY; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; FOLLICULAR CARCINOMA; GENE EXPRESSION; GRAVES DISEASE; HASHIMOTO DISEASE; HEAD AND NECK CANCER; HUMAN; HYPOPHYSIS TUMOR; KIDNEY CANCER; LIVER CELL CARCINOMA; LIVER HEMANGIOMA; LUNG SMALL CELL CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PROLACTINOMA; PROTEIN BLOOD LEVEL; RECTUM CANCER; REVIEW; STOMACH CANCER; SURVIVAL TIME; THYROID CARCINOMA; THYROID GLAND; UTERUS CANCER;

ANGIOGENESIS INHIBITORS; DIABETIC NEPHROPATHIES; ENDOCRINE GLAND NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83255170820     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. Endocr Rev 2003; 24: 600-632. (Pubitemid 37330584)
2. Sato K, Yamazaki K, Shizume K et al. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995; 96: 1295-1302.
3. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000; 166: 475-480.
4. Nagura S, Katoh R, Miyagi E et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 2001; 32: 10-7. (Pubitemid 32150622)
5. Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999; 161: 41-49. (Pubitemid 29170190)
6. Risau W Mechanisms of angiogenesis. Nature 1997; 386: 671-674. (Pubitemid 27193480)
7. Goth MI, Hubina E, Raptis S et al. Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech 2003; 60: 98-106. (Pubitemid 36055238)
8. Fenton C, Patel A, Dinauer C et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000; 10: 349-357. (Pubitemid 30256865)
9. Soh EY, Duh QY, Sobhi SA et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997; 82: 3741-3747. (Pubitemid 27509365)
10. Capp C, Wajner SM, Siqueira DR et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010; 20: 863-871.
11. Salajegheh A, Smith RA, Kasem K et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol 2011; 37: 93-99.
12. Nersita R, Matrone A, Klain M et al. Decreased serum vascular endothelial growth factor-D (VEGF-D) levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2011; [Epub ahead of print]. doi: 10.1111/j.1365-2265.2011.04183.x
13. Cristina C, Perez-Millan MI, Luque G et al. VEGF and CD31 association in pituitary adenomas. Endocr Pathol 2010; 21: 154-160.
14. McCabe CJ, Boelaert K, Tannahill LA et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002; 87: 4238-4244.
15. Renner U, Lohrer P, Schaaf L et al. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology 2002; 143: 3759-3765. (Pubitemid 35244353)
16. Marek B, Kajdaniuk D, Kos-Kudła B et al. Acromegaly and the risk of cancer. Pathophysiology 2001; 8: 69-75. (Pubitemid 33108982)
17. Garcia de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogs. Clin Endocrinol (Oxf) 2002; 57: 425-441.
18. Yarman S, Kurtulmus N, Canbolat A et al. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett 2010; 31: 823-828.
19. Miyajima K, Takekoshi S, Itoh J et al. Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 rats: animal model of VEGF-targeted therapy for human endocrine tumors. Acta Histochem Cytochem 2010; 43: 33-44.
20. Luque GM, Perez-Millán MI, Ornstein AM et al. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 2011; 337: 766-774.
21. Xiao Z, Liu Q, Mao F et al. TNF-a-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas. Int J Mol Sci 2011; 12: 4165-4179.
22. Khoury CC, Ziyadeh FN. Angiogenic factors. Contrib Nephrol 2011; 170: 83-92.
23. Shi B, Wang X, Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology 2001; 48: 1145-1148. (Pubitemid 32761706)
24. Paleolog EM, Young S, Stark AC et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-1265. (Pubitemid 28313429)
25. Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv) 2011; 53: 44-50.
26. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907; 2: 1236-1240.
27. Ehrmann RL, Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst 1968; 41: 1329-1341.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
29. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature. 2000; 407: 249-257.
30. Pircher A, Medinger M, Drevs J. Liver cancer: Targeted future options. World J Hepatol. 2011; 3: 38-44.
31. Zhu AX, Duda DG, Sahani DV et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8: 292-301.
32. Jubb AM, Pham TQ, Hanby AM et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1 alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 2004; 57: 504-512. (Pubitemid 38621796)
33. Fukumura D, Xavier R, Sugiura T et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725. (Pubitemid 28436004)
34. Harmey JH, Dimitriadis E, Kay E et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 1998; 5: 271-278. (Pubitemid 28249320)
35. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996; 15: 165-176. (Pubitemid 26236114)
36. Goldfarb SB, Hudis C, Dickler MN. Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol 2011; 3: 85-93.
37. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447. (Pubitemid 17009577)
38. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392.
39. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor Endocr Rev 1997; 18: 4-25. (Pubitemid 27076453)
40. Yamaguchi R, Yano H, Iemura A et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77. (Pubitemid 28299987)
41. Shimada H, Takeda A, Nabeya Y et al. Clinical significnace of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-669. (Pubitemid 32735204)
42. Broil R, Erdmann H, Duchrow M et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumor marker in patients with colorectal cancer? Eur J Surg Oncol 2001; 27: 37-42. (Pubitemid 32229693)
43. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000; 20: 5109-5112. (Pubitemid 32319090)
44. Gornall RJ, Anthony FW, Coombes EJ et al. Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement. Int J Gynecol Cancer 2001; 11: 164-166. (Pubitemid 32381666)
45. Holzer G, Obermair A, Koschat M et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 2001; 36: 601-604. (Pubitemid 32402155)
46. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936. (Pubitemid 32994827)
47. Salgado R, Benoy I, Weytjens R et al. Arteriovenous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002; 87: 1437-1444. (Pubitemid 36044320)
48. Dabrosin C. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 2003; 88: 2695-2698. (Pubitemid 36724444)
49. Maeda K, Chung YS, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863. (Pubitemid 26061277)
50. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930-934. (Pubitemid 27401946)
51. Wong MP, Cheung N, Yuen ST et al. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumor progression. Int J Cancer 1999; 81: 845-850. (Pubitemid 29249965)
52. Ishigami SI, Arii S, Furutani M et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-1384. (Pubitemid 28495254)
53. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
54. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 145.
55. Boocock CA, Chermock-Jones DS, Sharkey AM et al. Expression of vascular endothelial growth factor and its receptor flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
56. Volm M, Mattern J, Koomagi R. Inverse between apoptotic (Fas ligand, caspase-3) and angiogenic (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res. 1999; 19: 1669-1671. (Pubitemid 29392721)
57. Rofstad EK, Danielsen T. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 1998; 77: 897-902. (Pubitemid 28101776)
58. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-848.
59. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-4735. (Pubitemid 23304407)
60. Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-1262. (Pubitemid 24057094)
61. Suzuki K, Hayashi N, Miyamoto Y et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996; 56: 3004-3009. (Pubitemid 26199745)
62. El-Assal ON, Yamanoi A, Soda Y et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhosis liver. Hepatology 1998; 27: 1554-1562. (Pubitemid 28264678)
63. Zender L, Kubicka S. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008; 31: 550-555.
64. Sugimachi K, Tanaka S, Terashi T et al. The mechanism of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002; 131 (Suppl 1): S135-S141. (Pubitemid 34118629)
65. Yao DF, Wu XH, Zhu Y et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220-226. (Pubitemid 40790169)
66. Nanashima A, Ito M, Sekine I et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 1998; 43: 2634-2640. (Pubitemid 29034916)
67. Marschall Z, Cramer T, Hocker M et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001; 48: 87-96. (Pubitemid 32042647)
68. Brodsky SV, Mendelev N, Melamed M et al. Vascular density and VEGF expression in hepatic lesions. J Gastrointestin Liver Dis 2007; 16: 373-377.
69. Deli G, Jin CH, Mu R et al. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11: 960-963. (Pubitemid 40347745)
70. Claudio PP, Russo G, Kumar CACY et al. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 3509-3517. (Pubitemid 38685460)
71. Jeng KS, Sheen IS, Wang YC et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J Gastroenterol 2004; 10: 676-681.
72. Poon RTP, Lau CPY, Cheung ST et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003; 63: 3121-3126.
73. Yoshiji H, Kuriyama S, Yoshii J et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998; 28: 1489-1496. (Pubitemid 28549117)
74. Sawant S, Aparicio S, Tink AR et al. Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature. Biochem Biophys Res Commun 2004; 325: 408-413. (Pubitemid 39458010)
75. Ng IO, Poon RT, Lee JM et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001; 116: 838-845. (Pubitemid 33108154)
76. Shimamura T, Saito S, Morita K et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15: 640-646. (Pubitemid 30435715)
77. Yoshiji H, Kuriyama S, Yoshii J et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-842. (Pubitemid 34258377)
78. Jinno K, Tanimizu M, Hyodo I et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33: 376-382. (Pubitemid 28263653)
79. Miyashita M, Tajiri T, Yanagi K et al. Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology 2003; 50: 308-309. (Pubitemid 36390506)
80. Chao Y, Li CP, King KL et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-362. (Pubitemid 40486931)
81. Ye SL. Research on recurrence and metastasis of hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19 (suppl): S264-S265.
82. Dupuy E, Hainaud R Villemain A et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in transgenic mouse model. J Hepatol 2003; 38: 793-802. (Pubitemid 36613346)
83. Fang J, Yan L, Swing Y et al. HIF-1 alpha-mediated upregulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001; 61: 5731-5735. (Pubitemid 32769087)
84. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000; 62 (suppl 1): 92-99.
85. Blicharz-Dorniak J, Kos-Kudła B, Kudła M et al. Polypeptide growth factors in gastroenteropancreatic neuroendocrine tumours. Endokrynol Pol 2007; 58: 42-50.
86. Marschall Z, Scholz A, Cramer T et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-448. (Pubitemid 36432418)
87. Xu H, Shi BM, Lu XF et al. Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats. World J Gastroenterol 2008; 14: 2349-2357. (Pubitemid 351877605)
88. Taniguchi E, Sakisaka S, Matsuo K et al. Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001; 49: 121-130.
89. Mahajan D, Miller C, Hirose K et al. Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. J Hepatol 2008; 49: 867-870.
90. Zorzi D, Chun YS, Madoff DC et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008; 15: 2765-2772.
91. Commander H, Whiteside G, Perry C. Vandetanib: first global approval. Drugs 2011; 71: 1355-1365.
92. Elman MJ, Bressler NM, Qin H et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
93. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
94. Porta M, Maldari P, Mazzaglia F. New approaches to the treatment of diabetic retinopathy. Diabetes Obes Metab 2011; 13: 784-790.
95. Marchand GS, Noiseux N, Tanguay JF et al. Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am J Physiol 2002; 282: H194-H204. (Pubitemid 34654150)
96. Van Buren G 2nd, Yang AD, Dallas NA et al. Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008; 26: 1836-1842.
97. Yoshiji H, Noguchi R, Ikenaka Y et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem 2007; 14: 2749-2754. (Pubitemid 350130918)
98. Moreno M, Ramalho LN, Sancho-Bru P et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2008; 0: 00462.2007v1.
99. Turkay C, Yonem O, Arici S et al. Effect of angiotensin - converting enzyme inhibition on experimental hepatic fibrogenesis. Dig Dis Sci 2008; 53: 789-793. (Pubitemid 351317094)
100. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208: 516-518. (Pubitemid 10032881)
101. Sidky YA, Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-5161. (Pubitemid 17146488)
102. Slaton JW, Perrotte P, Inoue K et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734. (Pubitemid 29493945)
103. Ozawa S, Shinohara H, Kanayama HO et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by sytemic administration of interferon-alpha. Neoplasia 2001; 3: 154-164. (Pubitemid 32410356)
104. Gutterman JU. Cytokine therapeutics: lessons from interferon-alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205.
105. Palmieri G, Montella L, Martignetti A et al. Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report. Oncol Rep 2000; 7: 145-149.
106. Patt S, Sampaolo S, Theallier-Janko A et al. Cerebral angiogenesis triggered by severe chronic hypoxia displays regional differences. J Cereb Blood Flow Metab 1997; 17: 801-806. (Pubitemid 27427584)
107. Bass MB, Sherman SI, Schlumberger MJ et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010; 95: 5018-5027.